Developing precision medicine for bladder cancer Review
| Authors: | Guercio, B. J.; Iyer, G.; Rosenberg, J. E. |
| Review Title: | Developing precision medicine for bladder cancer |
| Keywords: | cancer chemotherapy; gene mutation; review; bevacizumab; cisplatin; doxorubicin; erlotinib; placebo; drug dose reduction; drug withdrawal; unspecified side effect; gemcitabine; adjuvant therapy; chemotherapy; methotrexate; biomarkers; biological marker; dna repair; cancer immunotherapy; gene expression profiling; epidermal growth factor receptor; epidermal growth factor receptor 2; bladder cancer; fibroblast growth factor receptor 3; phosphatidylinositol 3 kinase; protein p53; vinblastine; carcinogenesis; cell heterogeneity; docetaxel; clinical study; immunotherapy; microsatellite instability; cardiotoxicity; gefitinib; urothelial carcinoma; dna damage response; targeted therapy; bile duct carcinoma; trastuzumab; transitional cell carcinoma; lapatinib; vinflunine; pertuzumab; olaparib; personalized medicine; programmed death 1 ligand 1; molecularly targeted therapy; muscle invasive bladder cancer; machine learning; afatinib; nivolumab; rucaparib; dovitinib; azd 4547; fgfr3 gene; buparlisib; human; priority journal; precision medicine; pembrolizumab; durvalumab; erdafitinib; infigratinib; atezolizumab; mutational load; vistusertib; trastuzumab deruxtecan; pemigatinib; multiomics; adavosertib; danvatirsen; rogaratinib; vofatamab |
| Journal Title: | Hematology/Oncology Clinics of North America |
| Volume: | 35 |
| Issue: | 3 |
| ISSN: | 0889-8588 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-06-01 |
| Start Page: | 633 |
| End Page: | 653 |
| Language: | English |
| DOI: | 10.1016/j.hoc.2021.02.008 |
| PUBMED: | 33958155 |
| PROVIDER: | scopus |
| PMCID: | PMC8108703 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 June 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
